Breast cancer is the most commonly diagnosed cancer in women in China. The disease has been managed primarily through chemotherapy in China, but several novel, premium-priced targeted therapies—…
Chemotherapy remains the dominant cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the metastatic setting. Patient biomarker status (e.g., BRAF,…
China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved for treatment—trastuzumab (Roche’s Herceptin,…
Breast cancer is the most commonly diagnosed cancer in women in China. The disease has been managed primarily through chemotherapy in China, but several novel, premium-priced targeted therapies—…
Bladder cancer is the eighth most commonly diagnosed cancer in China. The bladder cancer therapy market is set to enter a competitive and dynamic period of rapid growth, fueled by one of the most…
Chemotherapy and hormonal therapy have been the mainstay treatments of advanced endometrial carcinoma, but treatment is becoming more directed, as a result of tumor analysis. Immune checkpoint…
Bladder cancer is the eighth most commonly diagnosed cancer in China. The bladder cancer therapy market is set to enter a competitive and dynamic period of rapid growth, fueled by one of the most…
The treatment landscape for squamous cell carcinoma of the head and neck (SCCHN) witnessed a major change in 2019 with the approval of Merck & Co.’s Keytruda for untreated recurrent or metastatic…
Hormonal agents are the mainstay treatment for prostate cancer and are routinely used in all lines of therapy, even as novel agents like Orgovyx (Myovant) enter the treatment algorithm. Zytiga (…
The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment…
Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates…
Of the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China’…
Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Current lipid-modifying therapies include statins, ezetimibe, fibrates, omega-3 fatty acid compounds…
Type 2 diabetes (T2D) remains one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Several traditional drug classes such as biguanides and alpha-…
Of the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China’…